Early  	Early  	 RB	O
neutral  	neutral  	 JJ	B-NP
prebiotic  	prebiotic  	 JJ	I-NP
oligosaccharide  	oligosaccharide  	 JJ	I-NP
supplementation  	supplementation  	 NN	I-NP
reduces  	reduces  	 VBZ	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
some  	some  	 DT	O
allergic  	allergic  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
5  	5  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
life  	life  	 NN	O
A  	A  	 DT	O
mixture  	mixture  	 NN	O
of  	of  	 IN	O
neutral  	neutral  	 JJ	B-NP
prebiotic  	prebiotic  	 JJ	I-NP
oligosaccharides  	oligosaccharides  	 NN	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
reduce  	reduce  	 VB	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AD 	AD 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
allergy  	allergy  	 NN	B-NP
associated  	associated  	 VBN	I-NP
symptoms  	symptoms  	 NNS	I-NP
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
2  	2  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
if  	if  	 IN	O
this  	this  	 DT	O
protective  	protective  	 JJ	B-NP
effect  	effect  	 NN	I-NP
against  	against  	 IN	O
allergy  	allergy  	 NN	B-NP
lasted  	lasted  	 VBD	O
beyond  	beyond  	 IN	O
the  	the  	 DT	O
intervention  	intervention  	 NN	B-NP
period  	period  	 NN	I-NP
until  	until  	 IN	O
5  	5  	 CD	O
y  	y  	 NN	O
of  	of  	 IN	O
age 	age 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
a  	a  	 DT	O
prospective 	prospective 	 JJ	O
,  	,  	 ,	O
double  	double  	 RB	O
blind 	blind 	 JJ	O
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
fashion 	fashion 	 NN	O
,  	,  	 ,	O
healthy  	healthy  	 JJ	O
term  	term  	 NN	B-NP
infants  	infants  	 NNS	I-NP
at  	at  	 IN	O
risk  	risk  	 NN	O
of  	of  	 IN	O
atopy  	atopy  	 NN	B-NP
were  	were  	 VBD	O
fed  	fed  	 VBN	O
either  	either  	 RB	O
a  	a  	 DT	O
prebiotic-supplemented  	prebiotic-supplemented  	 JJ	B-NP
( 	( 	 -LRB-	O
0.8  	0.8  	 CD	O
g 	g 	 CD	O
/ 	/ 	 CD	O
100  	100  	 CD	O
ml  	ml  	 CD	O
scGOS 	scGOS 	 JJ	O
/ 	/ 	 NNP	O
lcFOS 	lcFOS 	 NNP	O
)  	)  	 -RRB-	O
or  	or  	 CC	O
placebo-supplemented  	placebo-supplemented  	 NNP	O
( 	( 	 -LRB-	O
0.8  	0.8  	 CD	O
g 	g 	 CD	O
/ 	/ 	 CD	O
100  	100  	 CD	O
ml  	ml  	 CD	O
maltodextrin 	maltodextrin 	 CD	B-NP
)  	)  	 -RRB-	O
hypoallergenic  	hypoallergenic  	 JJ	B-NP
formula  	formula  	 NN	I-NP
during  	during  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
6  	6  	 CD	O
mo  	mo  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
Following  	Following  	 VBG	O
this  	this  	 DT	O
intervention  	intervention  	 NN	B-NP
period 	period 	 NN	I-NP
,  	,  	 ,	O
follow-up  	follow-up  	 NNP	O
continued  	continued  	 VBD	O
until  	until  	 IN	O
5  	5  	 CD	O
y  	y  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
present  	present  	 JJ	O
study  	study  	 NN	O
evaluated  	evaluated  	 NNS	O
( 	( 	 -LRB-	O
i 	i 	 FW	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
cumulative  	cumulative  	 JJ	B-NP
incidence  	incidence  	 NN	I-NP
of  	of  	 IN	I-NP
allergic  	allergic  	 JJ	I-NP
manifestations  	manifestations  	 NNS	I-NP
during  	during  	 IN	O
5  	5  	 CD	O
y 	y 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
( 	( 	 -LRB-	O
ii 	ii 	 LS	O
)  	)  	 -RRB-	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 NN	O
and  	and  	 CC	O
persistent  	persistent  	 JJ	O
allergic  	allergic  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
at  	at  	 IN	O
5  	5  	 CD	O
y 	y 	 NNS	O
.  	.  	 .	O
Monitored  	Monitored  	 VBN	O
allergic  	allergic  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
were  	were  	 VBD	O
AD 	AD 	 NNP	O
,  	,  	 ,	O
recurrent  	recurrent  	 JJ	O
wheezing 	wheezing 	 NN	O
,  	,  	 ,	O
allergic  	allergic  	 JJ	B-NP
rhinoconjunctivitis  	rhinoconjunctivitis  	 NN	I-NP
and  	and  	 CC	O
urticaria 	urticaria 	 NN	B-NP
.  	.  	 .	O
Ninety-two  	Ninety-two  	 JJ	O
children  	children  	 NNS	O
( 	( 	 -LRB-	O
50  	50  	 CD	O
in  	in  	 IN	O
placebo  	placebo  	 JJ	O
group 	group 	 NN	O
,  	,  	 ,	O
42  	42  	 CD	O
in  	in  	 IN	O
intervention  	intervention  	 NN	B-NP
group 	group 	 NN	I-NP
)  	)  	 -RRB-	O
completed  	completed  	 VBD	O
the  	the  	 DT	O
5-y  	5-y  	 NNP	B-NP
follow-up 	follow-up 	 NNP	I-NP
.  	.  	 .	O
The  	The  	 DT	O
5-y  	5-y  	 JJ	B-NP
cumulative  	cumulative  	 JJ	I-NP
incidences  	incidences  	 NN	I-NP
of  	of  	 IN	O
any  	any  	 DT	O
allergic  	allergic  	 JJ	B-NP
manifestation  	manifestation  	 NN	I-NP
and  	and  	 CC	O
atopic  	atopic  	 JJ	B-NP
dermatitis  	dermatitis  	 NN	I-NP
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
scGOS 	scGOS 	 JJ	B-NP
/ 	/ 	 CD	I-NP
lcFOS  	lcFOS  	 JJ	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
30.9 	30.9 	 CD	O
,  	,  	 ,	O
19.1  	19.1  	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
placebo  	placebo  	 VB	O
group  	group  	 NN	O
( 	( 	 -LRB-	O
66 	66 	 CD	O
,  	,  	 ,	O
38  	38  	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.01  	0.01  	 CD	O
and  	and  	 CC	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Children  	Children  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
scGOS 	scGOS 	 JJ	B-NP
/ 	/ 	 CD	I-NP
lcFOS  	lcFOS  	 JJ	I-NP
group  	group  	 NN	I-NP
tended  	tended  	 VBD	O
to  	to  	 TO	O
have  	have  	 VB	O
a  	a  	 DT	O
lower  	lower  	 JJR	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
allergic  	allergic  	 JJ	B-NP
rhinoconjunctivitis 	rhinoconjunctivitis 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
allergic  	allergic  	 JJ	B-NP
urticaria  	urticaria  	 NNS	I-NP
( 	( 	 -LRB-	O
4.8  	4.8  	 CD	O
vs  	vs  	 CD	O
16 	16 	 CD	O
%  	%  	 NN	O
for  	for  	 IN	O
both  	both  	 DT	O
manifestations 	manifestations 	 NN	B-NP
,  	,  	 ,	O
p=0.08 	p=0.08 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
difference  	difference  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
cumulative  	cumulative  	 JJ	B-NP
incidence  	incidence  	 NN	I-NP
of  	of  	 IN	O
recurrent  	recurrent  	 JJ	O
wheezing 	wheezing 	 NN	O
.  	.  	 .	O
With  	With  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
prevalences  	prevalences  	 NN	O
at  	at  	 IN	O
5  	5  	 CD	O
y 	y 	 NN	O
,  	,  	 ,	O
intervention  	intervention  	 NN	B-NP
group  	group  	 NN	I-NP
had  	had  	 VBD	O
significantly  	significantly  	 RB	O
lower  	lower  	 JJR	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
any  	any  	 DT	O
persistent  	persistent  	 JJ	O
allergic  	allergic  	 JJ	B-NP
manifestation  	manifestation  	 NN	I-NP
and  	and  	 CC	O
rhinoconjunctivitis  	rhinoconjunctivitis  	 NNS	B-NP
( 	( 	 -LRB-	O
4.8 	4.8 	 CD	O
,  	,  	 ,	O
2.4  	2.4  	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
placebo  	placebo  	 VB	O
( 	( 	 -LRB-	O
26 	26 	 CD	O
,  	,  	 ,	O
14  	14  	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
respectively 	respectively 	 RB	O
)  	)  	 -RRB-	O
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.01  	0.01  	 CD	O
and  	and  	 CC	O
=0.05 	=0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Prevalence  	Prevalence  	 NNP	O
of  	of  	 IN	O
persistent  	persistent  	 JJ	O
AD  	AD  	 NNP	O
tended  	tended  	 VBD	O
to  	to  	 TO	O
be  	be  	 VB	O
lower  	lower  	 JJR	O
in  	in  	 IN	O
the  	the  	 DT	O
intervention  	intervention  	 NN	B-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
2.4  	2.4  	 CD	O
vs  	vs  	 CD	O
12 	12 	 CD	O
% 	% 	 NN	O
,  	,  	 ,	O
p=  	p=  	 CD	O
0.09 	0.09 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Although  	Although  	 IN	O
intervention  	intervention  	 NN	B-NP
group  	group  	 NN	I-NP
had  	had  	 VBD	O
75 	75 	 CD	O
%  	%  	 NN	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
persistent  	persistent  	 JJ	O
wheezing  	wheezing  	 NNS	O
( 	( 	 -LRB-	O
4.8  	4.8  	 CD	O
vs  	vs  	 CD	O
14  	14  	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
no  	no  	 DT	O
significance  	significance  	 NN	B-NP
was  	was  	 VBD	O
shown 	shown 	 VBN	O
.  	.  	 .	O
Oligosaccharide  	Oligosaccharide  	 JJ	B-NP
prebiotics  	prebiotics  	 NNS	I-NP
( 	( 	 -LRB-	O
scGOS 	scGOS 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
lcFOS 	lcFOS 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
when  	when  	 WRB	O
started  	started  	 VBD	O
early  	early  	 RB	O
in  	in  	 IN	O
life  	life  	 NN	O
have  	have  	 VBP	O
a  	a  	 DT	O
protective  	protective  	 JJ	B-NP
effect  	effect  	 NN	I-NP
against  	against  	 IN	O
allergic  	allergic  	 JJ	B-NP
manifestations  	manifestations  	 NNS	I-NP
in  	in  	 IN	O
high  	high  	 JJ	O
risk  	risk  	 NN	B-NP
infants 	infants 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
protection  	protection  	 NN	O
lasts  	lasts  	 VBZ	O
beyond  	beyond  	 IN	O
infancy  	infancy  	 NN	O
until  	until  	 IN	O
5  	5  	 CD	O
y  	y  	 NN	O
of  	of  	 IN	O
life 	life 	 NN	O
,  	,  	 ,	O
for  	for  	 IN	O
AD  	AD  	 NNP	O
and  	and  	 CC	O
allergic  	allergic  	 JJ	B-NP
rhinoconjunctivitis 	rhinoconjunctivitis 	 NN	I-NP
.  	.  	 .	O
Long-term  	Long-term  	 JJ	O
follow-up  	follow-up  	 JJ	B-NP
studies  	studies  	 NNS	I-NP
in  	in  	 IN	O
larger  	larger  	 JJR	O
populations  	populations  	 NNS	O
are  	are  	 VBP	O
warranted  	warranted  	 VBN	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
preventive  	preventive  	 JJ	I-NP
effect  	effect  	 NN	I-NP
of  	of  	 IN	O
this  	this  	 DT	O
mixture  	mixture  	 NN	O
on  	on  	 IN	O
asthma 	asthma 	 NN	B-NP
.  	.  	 .	O
